eMedicine Specialties > Dermatology > Photo-Related Diseases
Hydroa Vacciniforme: Follow-up
Updated: Jul 24, 2008
Follow-up
Further Inpatient Care
- HV is managed on an outpatient basis.
Further Outpatient Care
- Patients with extracutaneous findings associated with HV should be referred to the appropriate specialist.
Inpatient & Outpatient Medications
- See Medical Care and Medication.
Deterrence/Prevention
- Avoiding the sun, frequently applying high SPF sunscreens with UV-A blocking agents, and wearing protective clothing may prevent episodes of HV.
Complications
- Complications are rare in HV. The most common severe sequela is the varioliform scarring.
Prognosis
- The prognosis is excellent; HV remits by adolescence.
Patient Education
- Patients are advised regarding strict sun avoidance, frequent application of high SPF sunscreens with UV-A blocking agents, and protective clothing.
Miscellaneous
Medicolegal Pitfalls
- Failure to educate the patient regarding sun avoidance measures is poor management. The physician should also monitor for adverse effects and laboratory abnormalities while the patient is on oral therapy, particularly antimalarials.
Special Concerns
- Rigid sun avoidance may be socially devastating for the pediatric patient with HV. The physician should work closely with the parents and management team in supporting and educating the child regarding this disease.
More on Hydroa Vacciniforme |
| Overview: Hydroa Vacciniforme |
| Differential Diagnoses & Workup: Hydroa Vacciniforme |
| Treatment & Medication: Hydroa Vacciniforme |
Follow-up: Hydroa Vacciniforme |
| Multimedia: Hydroa Vacciniforme |
| References |
| « Previous Page | Next Page » |
References
Yesudian PD, Sharpe GR. Hydroa vacciniforme with oral mucosal involvement. Pediatr Dermatol. Sep-Oct 2004;21(5):555-7. [Medline].
Jeng BH, Margolis TP, Chandra NS, McCalmont TH. Ocular findings as a presenting sign of hydroa vacciniforme. Br J Ophthalmol. Nov 2004;88(11):1478-9. [Medline].
Wisuthsarewong W, Leenutaphong V, Viravan S. Hydroa vacciniforme with ocular involvement. J Med Assoc Thai. Oct 1998;81(10):807-11. [Medline].
Kim WS, Yeo UC, Chun HS, Lee ES. A case of hydroa vacciniforme with unusual ear mutilation. Clin Exp Dermatol. Mar 1998;23(2):70-2. [Medline].
Halasz CL, Leach EE, Walther RR, Poh-Fitzpatrick MB. Hydroa vacciniforme: induction of lesions with ultraviolet A. J Am Acad Dermatol. Feb 1983;8(2):171-6. [Medline].
Annamalai R. Hydroa vacciniforme in three alternate siblings. Arch Dermatol. Feb 1971;103(2):224-5. [Medline].
Iwatsuki K, Ohtsuka M, Akiba H, Kaneko F. Atypical hydroa vacciniforme in childhood: from a smoldering stage to Epstein-Barr virus-associated lymphoid malignancy. J Am Acad Dermatol. Feb 1999;40(2 Pt 1):283-4. [Medline].
Iwatsuki K, Ohtsuka M, Harada H, Han G, Kaneko F. Clinicopathologic manifestations of Epstein-Barr virus-associated cutaneous lymphoproliferative disorders. Arch Dermatol. Sep 1997;133(9):1081-6. [Medline].
Magaña M, Sangüeza P, Gil-Beristain J, Sánchez-Sosa S, Salgado A, Ramón G, et al. Angiocentric cutaneous T-cell lymphoma of childhood (hydroa-like lymphoma): a distinctive type of cutaneous T-cell lymphoma. J Am Acad Dermatol. Apr 1998;38(4):574-9. [Medline].
Tokura Y, Ishihara S, Ohshima K, Hidano A, Koide M, Seo N, et al. Severe mosquito bite hypersensitivity, natural killer cell leukaemia, latent or chronic active Epstein-Barr virus infection and hydroa vacciniforme-like eruption. Br J Dermatol. May 1998;138(5):905-6. [Medline].
Iwatsuki K, Satoh M, Yamamoto T, Oono T, Morizane S, Ohtsuka M, et al. Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders. Arch Dermatol. May 2006;142(5):587-95. [Medline].
Yamamoto T, Tsuji K, Suzuki D, Morizane S, Iwatsuki K. A novel, noninvasive diagnostic probe for hydroa vacciniforme and related disorders: detection of latency-associated Epstein-Barr virus transcripts in the crusts. J Microbiol Methods. Feb 2007;68(2):403-7. [Medline].
Collins P, Ferguson J. Narrow-band UVB (TL-01) phototherapy: an effective preventative treatment for the photodermatoses. Br J Dermatol. Jun 1995;132(6):956-63. [Medline].
Ziering CL, Rabinowitz LG, Esterly NB. Antimalarials for children: indications, toxicities, and guidelines. J Am Acad Dermatol. May 1993;28(5 Pt 1):764-70. [Medline].
Bruderer P, Shahabpour M, Christoffersen S, André J, Ledoux M. Hydroa vacciniforme treated by a combination of beta-carotene and canthaxanthin. Dermatology. 1995;190(4):343-5. [Medline].
Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. May 2 1996;334(18):1150-5. [Medline].
The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. Apr 14 1994;330(15):1029-35. [Medline].
Blackwell V, McGregor JM, Hawk JL. Hydroa vacciniforme presenting in an adult successfully treated with cyclosporin A. Clin Exp Dermatol. Mar 1998;23(2):73-6. [Medline].
Rhodes LE, White SI. Dietary fish oil as a photoprotective agent in hydroa vacciniforme. Br J Dermatol. Jan 1998;138(1):173-8. [Medline].
Rhodes LE, Durham BH, Fraser WD, Friedmann PS. Dietary fish oil reduces basal and ultraviolet B-generated PGE2 levels in skin and increases the threshold to provocation of polymorphic light eruption. J Invest Dermatol. Oct 1995;105(4):532-5. [Medline].
Hashizume H, Tokura Y, Oku T, Iwamoto Y, Takigawa M. Photodynamic DNA-breaking activity of serum from patients with various photosensitivity dermatoses. Arch Dermatol Res. 1995;287(6):586-90. [Medline].
Ashurst PJ. Hydroa vacciniforme occurring in association with Hartnup disease. Br J Dermatol. Jul 1969;81(7):486-92. [Medline].
Bickers DR, Demar LK, DeLeo V, Poh-Fitzpatrick MB, Aronberg JM, Harber LC. Hydroa vacciniforme. Arch Dermatol. Aug 1978;114(8):1193-6. [Medline].
De Pietro U, Simoni R, Barbieri C, Girolomoni G. Hydroa vacciniforme persistent in a 60-year-old man. Eur J Dermatol. Jun 1999;9(4):311-2. [Medline].
Ferguson J, Ibbotson S. The idiopathic photodermatoses. Semin Cutan Med Surg. Dec 1999;18(4):257-73. [Medline].
Goldgeier MH, Nordlund JJ, Lucky AW, Sibrack LA, McCarthy MJ, McGuire J. Hydroa vacciniforme: diagnosis and therapy. Arch Dermatol. Aug 1982;118(8):588-91. [Medline].
Gu H, Chang B, Qian H, Li G. A clinical study on severe hydroa vacciniforme. Chin Med J (Engl). Aug 1996;109(8):645-7. [Medline].
Gupta G, Man I, Kemmett D. Hydroa vacciniforme: A clinical and follow-up study of 17 cases. J Am Acad Dermatol. Feb 2000;42(2 Pt 1):208-13. [Medline].
Raza N, Bari AU, Farooq M. Hydroa vacciniforme in an adolescent girl. J Coll Physicians Surg Pak. Jun 2007;17(6):359-61. [Medline].
Ruiz-Maldonado R, Parrilla FM, Orozco-Covarrubias ML, Ridaura C, Tamayo Sanchez L, Duran McKinster C. Edematous, scarring vasculitic panniculitis: a new multisystemic disease with malignant potential. J Am Acad Dermatol. Jan 1995;32(1):37-44. [Medline].
Sato K, Taguchi H, Maeda T, Minami H, Asada Y, Watanabe Y, et al. The primary cytotoxicity in ultraviolet-a-irradiated riboflavin solution is derived from hydrogen peroxide. J Invest Dermatol. Oct 1995;105(4):608-12. [Medline].
Taylor CR, Duke D. Blistering, scarring, and photosensitivity in a male teenager. Arch Dermatol. Oct 1999;135(10):1267, 1270. [Medline].
Yoon TY, Kim YG, Kim JW, Kim MK. Nodal marginal zone lymphoma in association with hydroa vacciniforme-like papulovesicular eruption, hypersensitivity to mosquito bites and insect bite-like reaction. Br J Dermatol. Jul 2005;153(1):210-2. [Medline].
Further Reading
Keywords
Bazin hydroa vacciniforme, HV, photodermatosis
Follow-up: Hydroa Vacciniforme